MCID: PLS009
MIFTS: 47

Plasma Cell Neoplasm

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Plasma Cell Neoplasm

MalaCards integrated aliases for Plasma Cell Neoplasm:

Name: Plasma Cell Neoplasm 12 14 69
Plasma Cell Dyscrasia 12 69
Paraproteinemias 42 69
Plasma Cell Tumour 12
Plasmacytic Tumor 12
Multiple Myeloma 69
Plasmacytoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:6536
MeSH 42 D010265
SNOMED-CT 64 277576009 71390001
UMLS 69 C1136084

Summaries for Plasma Cell Neoplasm

MalaCards based summary : Plasma Cell Neoplasm, also known as plasma cell dyscrasia, is related to lymphoma and monoclonal paraproteinemia. An important gene associated with Plasma Cell Neoplasm is MYOM2 (Myomesin 2), and among its related pathways/superpathways are B cell receptor signaling pathway (KEGG) and Epstein-Barr virus infection. The drugs Zoledronic acid and Bortezomib have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are cellular and hematopoietic system

Related Diseases for Plasma Cell Neoplasm

Diseases related to Plasma Cell Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
id Related Disease Score Top Affiliating Genes
1 lymphoma 30.4 CD40LG CD79A IL6
2 monoclonal paraproteinemia 12.0
3 refractory plasma cell neoplasm 12.0
4 necrobiotic xanthogranuloma 11.2
5 alcoholic neuropathy 10.9 CD40LG CD79A
6 calloso-genital dysplasia 10.9 CD40LG CD79A
7 variola major 10.9 CD40LG CD79A
8 mu chain disease 10.9 CD40LG CD79A
9 rabies 10.9 CD40LG CD79A
10 familial retinoblastoma 10.9 CD40LG CD79A
11 anti-basement membrane glomerulonephritis 10.9 CD40LG CD79A
12 microinvasive cervical squamous cell carcinoma 10.9 CD40LG CD79A
13 fetal erythroblastosis 10.9 CD40LG CD79A
14 spinal canal and spinal cord meningioma 10.9 CD40LG CD79A
15 trichostrongyloidiasis 10.9 CD40LG CD79A
16 leukodystrophy 10.9 CD40LG CD79A
17 retinal microaneurysm 10.9 CD40LG CD79A
18 heart septal defect 10.9 CD40LG CD79A
19 cryptorchidism arachnodactyly mental retardation 10.9 CD40LG CD79A
20 acute kidney tubular necrosis 10.8 CD40LG CD79A
21 secretory meningioma 10.8 CD40LG CD79A
22 hodgkin's lymphoma, nodular sclerosis 10.8 CD40LG CD79A
23 imperforate oropharynx-costo vetebral anomalies 10.8 CD40LG CD79A
24 malignant otitis externa 10.8 CD40LG CD79A
25 benign epilepsy with centrotemporal spikes 10.8 CD40LG CD79A
26 tongue cancer 10.8 CD40LG CD79A
27 nasopharyngeal disease 10.8 CD79A MYOM2
28 hydrops of gallbladder 10.8 CD40LG CD79A
29 gamma heavy chain disease 10.8 CD40LG CD79A
30 diabetic angiopathy 10.8 CD40LG CD79A
31 peripheral nerve schwannoma 10.8 B2M MYOM2
32 rosacea conjunctivitis 10.8 CD40LG CD79A
33 viral meningitis 10.8 CD40LG CD79A
34 combined thymoma 10.8 CD38 CD79A
35 heart fibrosarcoma 10.8 CD40LG CD79A
36 alopecia areata 10.8 CD40LG CD79A
37 kidney carcinoma in situ 10.8 CD40LG CD79A
38 46 xy gonadal dysgenesis 10.8 B2M CD79A
39 cardiac tuberculosis 10.7 CD40LG CD79A
40 dumping syndrome 10.7 CD40LG CD79A
41 plasmacytoma 10.7
42 leiomyosarcoma 10.7 CD40LG CD79A
43 periarthritis 10.7 CD40LG CD79A
44 colonic benign neoplasm 10.7 CD40LG CD79A
45 non-congenital cyst of kidney 10.7 B2M CD79A
46 multiple myeloma 10.7
47 cerebral neuroblastoma 10.7 CD40LG CD79A
48 cannabis dependence 10.7 CD40LG MAG
49 pancreatic vasoactive intestinal peptide producing tumor 10.7 CD40LG CD79A
50 membranoproliferative glomerulonephritis 10.7 CD40LG CD79A MYOM2

Comorbidity relations with Plasma Cell Neoplasm via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Bronchitis
Chronic Kidney Failure Deficiency Anemia
Heart Disease Monoclonal Paraproteinemia
Neutropenia Osteoporosis

Graphical network of the top 20 diseases related to Plasma Cell Neoplasm:



Diseases related to Plasma Cell Neoplasm

Symptoms & Phenotypes for Plasma Cell Neoplasm

MGI Mouse Phenotypes related to Plasma Cell Neoplasm:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.14 B2M CD19 CD38 CD40LG CD79A IL6
2 hematopoietic system MP:0005397 10.06 B2M CD19 CD38 CD40LG CD79A IL6
3 immune system MP:0005387 10 MAEA MAG MYC PCSK5 PTPRC B2M
4 digestive/alimentary MP:0005381 9.91 MYC NSD2 PCSK5 PTPRC B2M CD19
5 mortality/aging MP:0010768 9.9 B2M CD19 CD40LG IL6 MAEA MYC
6 neoplasm MP:0002006 9.43 B2M CD19 CD79A IL6 MYC PTPRC
7 nervous system MP:0003631 9.32 B2M CD19 CD40LG CD79A IL6 MAG

Drugs & Therapeutics for Plasma Cell Neoplasm

Drugs for Plasma Cell Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 684)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
2
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
4
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
6
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
7
Panobinostat Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 404950-80-7 6918837
8
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 191732-72-6 216326
9
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
10
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 148-82-3 4053 460612
11
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
12
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
13
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-98-1 2478
14
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
15
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24356-66-9 32326 21704
16
Apixaban Approved Phase 4,Phase 3,Phase 2 503612-47-3 10182969
17
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
18
Phentolamine Approved Phase 4 50-60-2 5775
19
Piperacillin Approved Phase 4,Phase 3 66258-76-2 43672
20
Tazobactam Approved Phase 4,Phase 3 89786-04-9 123630
21 Thiotepa Approved Phase 4,Phase 2,Phase 1 52-24-4 5453
22 Ixazomib Approved Phase 4,Phase 3,Phase 2,Phase 1 1072833-77-2
23
Liraglutide Approved Phase 4 204656-20-2 44147092
24
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 56-40-6 750
25
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
26
Pirarubicin Investigational Phase 4 72496-41-4
27 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1177-87-3
39 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
49 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2402)

id Name Status NCT ID Phase Drugs
1 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
2 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
3 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
4 Pseudohyponatremia of Multiple Myeloma is True Hyponatremia Unknown status NCT01425606 Phase 4
5 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
6 Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma Completed NCT01083602 Phase 4 panobinostat;bortezomib;dexamethasone
7 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
8 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone
9 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4 Bortezomib
10 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
11 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Completed NCT00622505 Phase 4 zoledronic acid
12 Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib Completed NCT01060202 Phase 4 No intervention
13 A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure Completed NCT01241396 Phase 4
14 Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. Completed NCT01026701 Phase 4 bortezomib
15 Quality of Life in Multiple Myeloma Patients Treated With Bortezomib Completed NCT01021592 Phase 4 bortezomib
16 A Retreatment Study With Bortezomib for Multiple Myeloma Completed NCT01030302 Phase 4 bortezomib
17 Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma Completed NCT02474563 Phase 4 Bortezomib;Melphalan;Prednisone
18 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
19 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Completed NCT00257114 Phase 4 bortezomib
20 An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade Completed NCT01675245 Phase 4 No intervention
21 REmoval of Free Light Chains. A COmpaRison of Three Different dialyzERs Completed NCT02950389 Phase 4
22 VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands Completed NCT00440765 Phase 4 bortezomib
23 ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. Completed NCT00440479 Phase 4 Bortezomib
24 Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) Completed NCT01005628 Phase 4 bortezomib
25 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
26 Retrospective Survey of Re-treatment With Bortezomib Completed NCT01524445 Phase 4
27 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
28 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
29 Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients Completed NCT00195533 Phase 4 piperacillin-tazobactam;glycopeptide
30 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
31 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
32 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
33 Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation Completed NCT01738373 Phase 4 Plerixafor
34 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Recruiting NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
35 An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (TOURMALINE MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
36 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
37 PDD vs PAD to Treat Initially Diagnosed MM Recruiting NCT02577783 Phase 4 Chemotherapy with PDD regimen;Chemotherapy with PAD regimen
38 Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse Active, not recruiting NCT01087008 Phase 4 zoledronic acid
39 Modified Bortezomib-based Combination Therapy for Multiple Myeloma Active, not recruiting NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
40 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Not yet recruiting NCT02958969 Phase 4 Apixaban;Placebo Oral Tablet
41 Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. Not yet recruiting NCT02006225 Phase 4 Plerixafor
42 Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat Not yet recruiting NCT02920190 Phase 4 Liraglutide
43 Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
44 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4 Epoetin Beta
45 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
46 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
47 Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
48 Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
49 Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
50 Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate

Search NIH Clinical Center for Plasma Cell Neoplasm

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: paraproteinemias

Genetic Tests for Plasma Cell Neoplasm

Anatomical Context for Plasma Cell Neoplasm

MalaCards organs/tissues related to Plasma Cell Neoplasm:

39
Bone, Bone Marrow, T Cells, B Cells, Kidney, Testes, Myeloid

Publications for Plasma Cell Neoplasm

Articles related to Plasma Cell Neoplasm:

(show top 50) (show all 53)
id Title Authors Year
1
Plasma cell neoplasm as a risk factor for early thrombosis of arteriovenous fistula. ( 28762615 )
2017
2
Plasma cell neoplasm with plasmablastic morphology mimicking acute leukemia. ( 28057674 )
2017
3
Accuracy of Bone Marrow Flow Cytometry Analysis in Patients With Plasma Cell Neoplasm in Thailand: A Single Institutional Study. ( 26796980 )
2016
4
Dual CD3 and CD4 positive plasma cell neoplasm with indistinct morphology: a diagnostic pitfall. ( 27133529 )
2016
5
Collision Tumor With Renal Cell Carcinoma and Plasmacytoma: Further Evidence of a Renal Cell and Plasma Cell Neoplasm Relationship? ( 27175345 )
2016
6
Plasma Cell Neoplasm Manifesting Initially as a Sub-Cutaneous Supra-Orbital Swelling. ( 26955130 )
2016
7
Cytology of plasma cell rich effusion in cases of plasma cell neoplasm. ( 27756988 )
2016
8
Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains. ( 26339430 )
2015
9
Osseous plasma cell neoplasm of the mandible for initial diagnosis of multiple myeloma: case report and literature review. ( 25861199 )
2015
10
Pediatric Pharyngeal IgD-positive Monoclonal Plasmacytoid and Plasma Cell Neoplasm. ( 25851555 )
2015
11
Image of the month : a rare presentation of a plasma cell neoplasm. ( 25333092 )
2014
12
Crystal-storing histiocytosis with IgD I_-associated plasma cell neoplasm. ( 25028748 )
2014
13
Nodal involvement of extranodal marginal zone lymphoma with extreme plasmacytic differentiation (Mott cell formation) simulating plasma cell neoplasm and lymphoplasmacytic lymphoma. ( 25548763 )
2014
14
Epstein-Barr virus-driven bone marrow aplasia and plasmacytosis mimicking a plasma cell neoplasm. ( 24405048 )
2014
15
Practical diagnostic approaches to composite plasma cell neoplasm and low grade B-cell lymphoma/clonal infiltrates in the bone marrow. ( 24395190 )
2014
16
Classical Hodgkin lymphoma with coexistant plasma cell neoplasm: A case report. ( 25308039 )
2014
17
Dysmegakaryocytopoiesis and maintaining platelet count in patients with plasma cell neoplasm. ( 23814762 )
2013
18
Intracellular and extracellular immunoglobulin crystals assuming a multitude of geometric shapes in an IgG-I> plasma cell neoplasm. ( 23720061 )
2013
19
Low levels of interleukin-1 receptor antagonist (IL-1RA) predict engraftment syndrome after autologous stem cell transplantation in POEMS syndrome and other plasma cell neoplasms. ( 23792270 )
2013
20
Plasma cell neoplasm associated chronic neutrophilic leukemia with membrane proximal and truncating CSF3R mutations. ( 24033109 )
2013
21
Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone. ( 22429092 )
2012
22
Familial haemophagocytic lymphohistiocytosis-related plasma cell neoplasm: a case report. ( 22774220 )
2012
23
Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH. ( 22658896 )
2012
24
CD3 expression in plasma cell neoplasm (multiple myeloma): a diagnostic pitfall. ( 23172088 )
2012
25
Lower incidence of plasma cell neoplasm is maintained in migrant Chinese to British Columbia: findings from a 30-year survey. ( 21851219 )
2011
26
Plasma cell neoplasm in conjunction with glioblastoma of the conus medullaris. ( 21325257 )
2011
27
A quantitative analysis of genomic instability in lymphoid and plasma cell neoplasms based on the PIG-A gene. ( 20060400 )
2010
28
Ophthalmic presentation of plasma cell neoplasm. ( 19617795 )
2009
29
Mandibular radiolucency. Plasma cell neoplasm. ( 19906620 )
2009
30
Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. ( 17363561 )
2007
31
Myc translocations in B cell and plasma cell neoplasms. ( 16815105 )
2006
32
CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms. ( 16759389 )
2006
33
Clinical implication of centrosome amplification in plasma cell neoplasm. ( 16373658 )
2006
34
Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. ( 15735016 )
2005
35
Peripheral neuropathy associated with experimental plasma cell neoplasm in the mouse. ( 3029337 )
1987
36
Treatment of plasma cell neoplasm with recombinant leukocyte A interferon and human lymphoblastoid interferon. ( 3917376 )
1985
37
Thyroid-gland plasma cell neoplasm (plasmacytoma). ( 7027992 )
1981
38
An unusual case of a plasma cell neoplasm with an IgG3lambda myeloma and a gamma3 heavy chain disease protein. ( 412532 )
1978
39
Plasma cell neoplasm involving the thyroid. ( 638958 )
1978
40
Tumor cell invasion of hepatocytes in transplantable plasma cell neoplasm of mice. ( 4344454 )
1972
41
Ploidy fluctuations of mouse plasma-cell neoplasm MSPC-1 during serial transplantation. ( 5157581 )
1971
42
Enzymatic determinants of responsiveness of the LPC-1 plasma cell neoplasm to fluorouracil and fluorodeoxyuridine. ( 4254308 )
1970
43
Studies on the murine plasma-cell neoplasm, X5563. II. Accelerated immunologic reactivity to transplanted tumor induced in C3H mice by transferred immune rabbit cells. ( 6053557 )
1967
44
PLASMA CELL NEOPLASM ARISING IN A CAF MOUSE. CHARACTERISTICS AND RESPONSE TO CERTAIN CHEMOTHERAPEUTIC AGENTS. ( 14207853 )
1964
45
BIOCHEMICAL EFFECTS OF DUAZOMYCIN A IN THE MOUSE PLASMA CELL NEOPLASM 70429. ( 14096421 )
1963
46
Azaserine resistance in a plasma-cell neoplasm without change in active transport of the inhibitor. ( 13861221 )
1962
47
A study on globulin formation by plasma-cell neoplasm (5563) transplantable in mice. ( 13684805 )
1961
48
Distinctive myeloma globulins associated with a new plasma cell neoplasm of strain C3H mice. ( 13821296 )
1960
49
Alterations of gamma globulin with plasma cell neoplasm in mice. ( 13675239 )
1959
50
Bence Jones proteinuria associated with a transplantable mouse plasma-cell neoplasm. ( 13821298 )
1959

Variations for Plasma Cell Neoplasm

Copy number variations for Plasma Cell Neoplasm from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17396 1 142600000 155000000 Gain Plasma-cell dyscrasia

Expression for Plasma Cell Neoplasm

Search GEO for disease gene expression data for Plasma Cell Neoplasm.

Pathways for Plasma Cell Neoplasm

GO Terms for Plasma Cell Neoplasm

Cellular components related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 B2M CD38 CD40LG NCAM1 PTPRC
2 external side of plasma membrane GO:0009897 9.17 B2M CD19 CD40LG CD79A IL6 NCAM1

Biological processes related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.67 B2M CD38 IL6 MYC
2 positive regulation of T cell proliferation GO:0042102 9.33 CD40LG IL6 PTPRC
3 negative regulation of gluconeogenesis GO:0045721 9.32 IL6 MAEA
4 negative regulation of bone resorption GO:0045779 9.26 CD38 IL6
5 B cell proliferation GO:0042100 9.13 CD40LG CD79A PTPRC
6 B cell receptor signaling pathway GO:0050853 8.92 CD19 CD38 CD79A PTPRC

Sources for Plasma Cell Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....